Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tenofovir
Drug ID BADD_D02154
Description Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate.[A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog.[A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order to obtain oral bioavailability.[A18473, A178360]
Indications and Usage Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.[A178330] To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, [tenofovir alafenamide] and [tenofovir disoproxil].
Marketing Status experimental; investigational
ATC Code J05AF07
DrugBank ID DB14126
KEGG ID D06074
MeSH ID D000068698
PubChem ID 464205
TTD Drug ID D0D9HW
NDC Product Code Not Available
UNII 99YXE507IL
Synonyms Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine | 9-PMPA (tenofovir) | 9-(2-Phosphonomethoxypropyl)adenine | 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer | 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer | Tenofovir Disoproxil Fumarate | Disoproxil Fumarate, Tenofovir | Fumarate, Tenofovir Disoproxil | Tenofovir Disoproxil | Disoproxil, Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 | (R)-9-(2-phosphonylmethoxypropyl)adenine | Viread
Chemical Information
Molecular Formula C9H14N5O4P
CAS Registry Number 147127-20-6
SMILES CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin cancer23.08.02.002; 16.03.02.0020.004265%Not Available
Skin disorder23.03.03.007--Not Available
Skin hyperpigmentation23.05.01.0030.004265%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Spinal osteoarthritis15.01.04.0030.001939%Not Available
Splenomegaly01.09.02.0010.002908%Not Available
Squamous cell carcinoma16.16.01.0020.001939%Not Available
Stillbirth18.01.02.002; 08.04.01.0060.012020%Not Available
Sudden death02.03.04.013; 08.04.01.0030.002908%
Synovitis15.04.02.0010.002908%Not Available
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.001939%Not Available
Tachypnoea22.02.01.0140.001939%Not Available
Therapeutic response decreased08.06.01.016--Not Available
Tongue neoplasm malignant stage unspecified16.13.07.003; 07.21.07.0030.001939%Not Available
Tooth disorder07.09.05.0010.007561%Not Available
Tooth loss12.01.17.026; 07.09.09.0010.114191%Not Available
Umbilical hernia07.16.03.0010.002908%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Vision blurred06.02.06.007; 17.17.01.010--
Vitamin D deficiency14.12.03.0030.005816%Not Available
Vitreous detachment12.01.04.005; 06.09.01.0020.001939%Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Yellow skin09.01.01.009; 08.01.03.046; 23.03.03.0420.006592%Not Available
Tubulointerstitial nephritis20.05.02.0020.003877%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.004847%Not Available
Musculoskeletal disorder15.03.05.0250.006592%Not Available
Osteopenia15.02.03.003; 14.04.04.0040.126793%Not Available
The 7th Page    First    Pre   7 8 9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene